Safer CD40/CD40L targeting needs selectivity for autoimmune diseases

This narrative review discusses the regulation of CD40/CD40L signaling in the context of autoimmune conditions. The conditions covered include rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome. The review does not report a specific sample size or study population because it is a narrative summary rather than a clinical trial. Early CD40/CD40L-targeted biologics have shown thromboembolic complications in the past. The review notes that serious adverse events were not reported in the specific context of the discussion but highlights historical safety concerns. Readers should understand that safer therapeutic targeting of this pathway will require greater selectivity. This selectivity is particularly important with respect to cell-specific signaling and Fc-mediated adverse effects. The main reason to be careful is that current approaches may not be specific enough to avoid these risks. Readers should take from this that developing more selective drugs is necessary before these treatments can be widely used for these conditions. The evidence is based on a narrative review, which means it summarizes existing knowledge rather than presenting new data from a specific experiment.